A new study published in The Lancet journal showed that patients with type 2 diabetes and symptomatic peripheral arterial ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and type 2 diabetes in the first ...

Patients (67 years old on average, about 25% women, 67% white) were randomized to receive semaglutide (1 mg) or placebo for one year (52 weeks). Researchers assessed maximal walking distance - the ...

The double-blind, randomised, placebo-controlled STRIDE trial achieved its primary endpoint, with semaglutide 1.0 mg demonstrating a superior and clinically meaningful improvement of 13% in maximum ...

And the mean improvement in walking distance in the semaglutide group was approximately 40 meters," Bonaca reported. An improvement of 20 meters on a flat surface would be considered clinically ...

Perspective from Eugenia Gianos, MD CHICAGO — Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, according to data from the ...

The trial achieved its primary endpoint, with semaglutide 1.0 mg demonstrating a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference ...

“The significant improvements in walking distance and patient-reported quality of life observed with semaglutide 1.0 mg in the STRIDE trial are promising and represent an important step forward ...